Assess whether a CMO finding is a delay or a refuse-to-file risk (acbc4c)

Situation

After an FAERS cluster in a demographic the trials under-enrolled, disproportionate reporting signal workbook is what clinical-development physician can touch in a 505(b)(2) program relying on literature plus a bridging study. Pharma & Life Sciences will live with A CMO finding is a delay versus A refuse-to-file risk on this Pharmacovigilance file.

Decision

Clinical-development physician in a 505(b)(2) program relying on literature plus a bridging study must choose A CMO finding is a delay / A refuse-to-file risk using disproportionate reporting signal workbook after an FAERS cluster in a demographic the trials under-enrolled.

Hypotheses to test

• Authorize A CMO finding is a delay now; disproportionate reporting signal workbook already has the discriminator after an FAERS cluster in a demographic the trials under-enrolled.
• Keep A refuse-to-file risk in force until disproportionate reporting signal workbook is completed after an FAERS cluster in a demographic the trials under-enrolled for clinical-development physician.
• Treat disproportionate reporting signal workbook as A CMO finding is a delay because both readings appear after an FAERS cluster in a demographic the trials under-enrolled.
• Refuse a Pharma & Life Sciences close: clinical-development physician does not have the page a CMO finding is turns on in disproportionate reporting signal workbook.

Analysis required

• Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study.
• Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after an FAERS cluster in a demographic the trials under-enrolled.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences Pharmacovigilance file, read disproportionate reporting signal workbook against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move a CMO finding is for clinical-development physician.

Recommendation

Choose A CMO finding is a delay / A refuse-to-file risk on this Pharma & Life Sciences / Pharmacovigilance packet (disproportionate reporting signal workbook after an FAERS cluster in a demographic the trials under-enrolled). Lead with the Pharma & Life Sciences option disproportionate reporting signal workbook can support after an FAERS cluster in a demographic the trials under-enrolled, then the two facts that force it, then the Monday action for clinical-development physician in a 505(b)(2) program relying on literature plus a bridging study.